Endocrine Autoimmune Diseases: Pathogenesis and Personalized Therapy
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 536
Special Issue Editors
Interests: endocrinology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
One of the most interesting and innovative field in endocrine research is that concerning the autoimmune diseases.
The endocrine glands are susceptible to autoimmune disorders, as they are highly vascularized and have a great number of hormones and pro-hormones that may act as autoantigens. The diagnosis and treatment of these disorders continue to represent a clinical challenge. The occurrence of hypophysitis, thyroiditis, adrenalitis, diabetes and gonaditis may impact on the survival and quality of life of the affected patients. In recent years, an increased number of inflammatory disorders of the endocrine glands have been recorded due to immunomodulatoy drugs, such as immunotherapy in cancer patients.
The investigation of autoimmune endocrine diseases is proving to be of crucial importance for early diagnosis and prompt management. Notably, if the management is delayed or not tailored, it can even be fatal.
Personalized therapy could be the answer to the challenge in therapy of endocrine autoimmune disorders and endocrine immunotherapy toxicity. According to the clinical, histological and molecular characteristics, the therapy can be tailored to the patient in order to obtain the maximum efficacy of the treatment and of the patient’s compliance. The prompt diagnosis of endocrine toxicity in cancer patients in immunotherapy is also an important factor and a great determinant to adherence to immunotherapy.
The Special Issue, entitled ‘Endocrine Autoimmune Diseases: Pathogenesis and Personalized Therapy’, invites research and papers concerning the autoimmune endocrine diseases and endocrine adverse events related to immunotherapy, their diagnosis, and their treatment.
Authors are invited to participate with clinical research articles, reviews, and communications.
Dr. Sabrina Chiloiro
Dr. Emilia Sbardella
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hypophysitis
- autoimmune endocrine diseases
- thyroiditis
- immunotherapy
- endocrine toxicity
